Literature DB >> 21595649

Methaemalbumin formation in sickle cell disease: effect on oxidative protein modification and HO-1 induction.

Madelyn S Hanson1, Barbora Piknova, Agnes Keszler, Anne R Diers, Xunde Wang, Mark T Gladwin, Cheryl A Hillery, Neil Hogg.   

Abstract

Normally, cell free haemoglobin is bound by haptoglobin and efficiently cleared. However, the chronic haemolysis in sickle cell disease (SCD) overwhelms haptoglobin binding capacity and protein turnover, resulting in elevated cell free haemoglobin. Cell free haemoglobin acts as both a scavenger of vasoactive nitric oxide and a pro-oxidant. In addition, methaemoglobin (metHb) releases the haem moiety, which can bind to albumin to form methaemalbumin (metHSA). This study used electron paramagnetic resonance to detect metHSA in SCD plasma and demonstrated that haptoglobin prevents haem transfer from metHb to HSA. MetHSA may either provide a second line of defence against haemoglobin/haem-mediated oxidation or contribute to the pro-oxidant environment of SCD plasma. We demonstrated that HSA inhibited oxidative protein modification induced by metHb. Additionally, we showed that while metHb induced haem oxygenase 1 (HO-1), an indicator of oxidative stress, HSA attenuated metHb induction of this enzyme, thereby limiting the potential benefits of HO-1. Furthermore, HO-1 induction by metHSA was less than HO-1 induction by equimolar metHb not bound to albumin. Our findings confirm the presence of metHSA in SCD and suggest that haem transfer from metHb to HSA reduces the oxidative effects of free haemoglobin/haem on endothelium with both beneficial (reduced protein oxidation) and potentially harmful (reduced HO-1 induction) outcomes.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595649      PMCID: PMC3145810          DOI: 10.1111/j.1365-2141.2011.08738.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  43 in total

1.  Pulmonary hypertension and NO in sickle cell.

Authors:  Mark T Gladwin; Robyn J Barst; Oswaldo L Castro; Victor R Gordeuk; Cheryl A Hillery; Gregory J Kato; Daniel B Kim-Shapiro; Roberto Machado; Claudia R Morris; Martin H Steinberg; Elliott P Vichinsky
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

Review 2.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

3.  Methods for imaging and detecting modification of proteins by reactive lipid species.

Authors:  Ashlee N Higdon; Brian P Dranka; Bradford G Hill; Joo-Yeun Oh; Michelle S Johnson; Aimee Landar; Victor M Darley-Usmar
Journal:  Free Radic Biol Med       Date:  2009-05-14       Impact factor: 7.376

4.  Bilirubin and glutathione have complementary antioxidant and cytoprotective roles.

Authors:  Thomas W Sedlak; Masoumeh Saleh; Daniel S Higginson; Bindu D Paul; Krishna R Juluri; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-13       Impact factor: 11.205

Review 5.  Heme degradation and vascular injury.

Authors:  John D Belcher; Joan D Beckman; Gyorgy Balla; Jozsef Balla; Gregory Vercellotti
Journal:  Antioxid Redox Signal       Date:  2010-02       Impact factor: 8.401

6.  Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease.

Authors:  Joan D Beckman; John D Belcher; Julie V Vineyard; Chunsheng Chen; Julia Nguyen; M Osita Nwaneri; M Gerard O'Sullivan; Evin Gulbahce; Robert P Hebbel; Gregory M Vercellotti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-17       Impact factor: 4.733

Review 7.  Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities.

Authors:  Agnieszka Loboda; Agnieszka Jazwa; Anna Grochot-Przeczek; Andrzej J Rutkowski; Jaroslaw Cisowski; Anupam Agarwal; Alicja Jozkowicz; Jozef Dulak
Journal:  Antioxid Redox Signal       Date:  2008-10       Impact factor: 8.401

8.  The interaction of nitric oxide with distinct hemoglobins differentially amplifies endothelial heme uptake and heme oxygenase-1 expression.

Authors:  Roberta Foresti; Sandip Bains; Filip Sulc; Patrick J Farmer; Colin J Green; Roberto Motterlini
Journal:  J Pharmacol Exp Ther       Date:  2006-02-22       Impact factor: 4.030

9.  Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.

Authors:  C Lanaro; C F Franco-Penteado; D M Albuqueque; S T O Saad; N Conran; F F Costa
Journal:  J Leukoc Biol       Date:  2008-11-12       Impact factor: 4.962

Review 10.  Hemoglobin and heme scavenging.

Authors:  Paolo Ascenzi; Alessio Bocedi; Paolo Visca; Fiorella Altruda; Emanuela Tolosano; Tiziana Beringhelli; Mauro Fasano
Journal:  IUBMB Life       Date:  2005-11       Impact factor: 3.885

View more
  11 in total

1.  Quantification of whole-brain oxygenation extraction fraction and cerebral metabolic rate of oxygen consumption in adults with sickle cell anemia using individual T2 -based oxygenation calibrations.

Authors:  Wenbo Li; Xiang Xu; Peiying Liu; John J Strouse; James F Casella; Hanzhang Lu; Peter C M van Zijl; Qin Qin
Journal:  Magn Reson Med       Date:  2019-09-04       Impact factor: 4.668

2.  Immuno-spin trapping of heme-induced protein radicals: Implications for heme oxygenase-1 induction and heme degradation.

Authors:  Ashutosh Kumar; Douglas Ganini; Leesa J Deterding; Marilyn Ehrenshaft; Saurabh Chatterjee; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2013-04-25       Impact factor: 7.376

Review 3.  The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises.

Authors:  Edward Gomperts; John D Belcher; Leo E Otterbein; Thomas D Coates; John Wood; Brett E Skolnick; Howard Levy; Gregory M Vercellotti
Journal:  Am J Hematol       Date:  2017-04-29       Impact factor: 10.047

4.  Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.

Authors:  Hui Wang; Wei Luo; Jintao Wang; Chiao Guo; Stephanie L Wolffe; Julia Wang; Eddy B Sun; Kori N Bradley; Andrew D Campbell; Daniel T Eitzman
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

Review 5.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

6.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

7.  Extracellular hemin crisis triggers acute chest syndrome in sickle mice.

Authors:  Samit Ghosh; Olufolake Adetoro Adisa; Prasanthi Chappa; Fang Tan; Kesmic Ann Jackson; David Robert Archer; Solomon Fiifi Ofori-Acquah
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Liming Milbauer; Fuad Abdulla; Abdu I Alayash; Ann Smith; Karl A Nath; Robert P Hebbel; Gregory M Vercellotti
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

9.  Oxidative Profile of Patients with Sickle Cell Disease.

Authors:  Charles Antwi-Boasiako; Gifty B Dankwah; Robert Aryee; Charles Hayfron-Benjamin; Eric S Donkor; Andrew D Campbell
Journal:  Med Sci (Basel)       Date:  2019-01-25

10.  Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Fuad Abdulla; Ping Zhang; Hao Nguyen; Phong Nguyen; Trevor Killeen; Sylvia M Miescher; Nathan Brinkman; Karl A Nath; Clifford J Steer; Gregory M Vercellotti
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.